Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

The absence of coronavirus in expressed prostatic secretion in COVID-19 patients in Wuhan city

Shiqi Zhang\textsuperscript{a,1}, Xiaobo Wang\textsuperscript{b,1}, Hong Zhang\textsuperscript{b}, Aihui Xu\textsuperscript{c}, Guanghe Fei\textsuperscript{c}, Xiao Jiang\textsuperscript{d}, Jun Tu\textsuperscript{e}, Guangbo Qu\textsuperscript{f}, Xihai Xu\textsuperscript{g, *}, Yonghuai Li\textsuperscript{h, **}

\textsuperscript{a} Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
\textsuperscript{b} Department of Emergency, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
\textsuperscript{c} Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
\textsuperscript{d} Department of Nephrology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
\textsuperscript{e} Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
\textsuperscript{f} Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei 230032, China
\textsuperscript{g} Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

ARTICLE INFO

Keywords:
COVID-19
SARS-CoV-2
Prostate
Expressed prostatic secretion

ABSTRACT

Due to the cellular entry of the novel coronavirus (SARS-CoV-2) modulated by angiotensin converting enzyme 2 (ACE2), the ACE2 bearing prostate is therefore hypothesized as a susceptible organ to COVID-19. To delineate whether the pathogenic SARS-CoV-2 of the coronavirus disease (COVID-19) could be detected in the expressed prostatic secretion (EPS), a total of ten male patients with confirmed COVID-19 were recruited. All patients were stratified into two groups: one group with positive nasopharyngeal swabbing SARS-CoV-2 within 3 days of the EPS taken day (PNS group, \( n = 3 \)) and the other group with previously positive nasopharyngeal swabbing SARS-CoV-2 but turned negative before the taken day (PNNS group, \( n = 7 \)). The COVID-19 patients showed elevated inflammatory indicators, i.e. C-reactive protein (3.28 (1.14, 33.33) mg/L), erythrocyte sedimentation rate (22.50 (8.00, 78.50) mm/h), and interleukin-6 (6.49 (4.96, 21.09) pg/ml). Serum IgM against SARS-CoV-2 was only positive in the PNS group, whereas serum IgG was positive for all patients. Furthermore, our data showed for the first time that none of the COVID-19 patients had positive SARS-CoV-2 RNA in EPS. To this end, this study found the negativity of SARS-CoV-2 in EPS and possibly exclude the sexual transmission of COVID-19.

1. Introduction

Currently, the novel coronavirus disease (COVID-19) has outbroken in China and exponentially spread along the world since the first case was diagnosed on December 2019 in Wuhan City of China \cite{1}. The pathogenic novel coronavirus (SARS-CoV-2), isolated from the nasal and pharyngeal secretion, was highly homologous with the coronavirus caused Severe Acute Respiratory Syndrome (SARS) \cite{2}. Owing to the lack of immunity this global pandemic increases sharply within a few months, which not only burns a large amount of health expenditure but seriously threatens lives.

The amputating of COVID-19 transmission route is one of the effective measures to prevent the continuing spread. This disease is believed to transmit by inhalation or contact with infected droplets, which is confirmed by the detection of coronavirus in nasopharyngeal swabs \cite{3} and saliva \cite{4} of COVID-19 patients. Apart from the respiratory tract, the SARS-CoV-2 could be also detected in urine and gastrointestinal tract (positive percentage: urine: 0.076%; stool: 0.30%; rectal swab: 0.30%) \cite{5}. Yet, to the best of our knowledge the detection of SARS-CoV-2 in the prostate or expressed prostatic secretion (EPS) has not been reported up till now.

Angiotensin converting enzyme 2 (ACE2) was firstly found as a modulator involved in the regulation of renin-angiotensin aldosterone system (RAAS) \cite{6}. It distributes specifically in alveolar epithelial cells, enterocytes of the small intestine and testis in SARS pathogenesis \cite{7}. ACE2 bearing cells are found to be more vulnerable to the attack of coronavirus since the coronavirus spike protein mediates the viral entry to its target cells \cite{8,9}. Indeed, ACE2 has been proved to be a putative...

\textsuperscript{*} Corresponding author at: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, No.281, Jixi Road, Hefei 230022, China.
\textsuperscript{**} Corresponding author at: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, No.281, Jixi Road, Hefei 230022, China.

E-mail addresses: 2xh@163.com (X. Xu), lyh6481@126.com (Y. Li).

\textsuperscript{1} Contributed equally to this manuscript as first authors.

https://doi.org/10.1016/j.reprotox.2020.06.006

Received 22 April 2020; Received in revised form 14 May 2020; Accepted 7 June 2020

Available online 10 June 2020

0890-6238/ © 2020 Published by Elsevier Inc.
receptor for COVID-19 recently [8]. This probably explains the pathogenesis of lung and intestine during SARS and COVID-19. The prostate is also one of the organs express abundant ACE2 [10]. Therefore, it is reasonable to hypothesize that the prostate may be affected by SARS-CoV-2. In this case male fertility could be influenced, and sexual transmission also needs to be taken into account. Yet, recent studies have found the absence of SARS-CoV-2 in the semen and testis [11,12] although the testis is an ACE rich organ. Hence, we aimed to delineate whether COVID-19 was transmitted via sex behavior. Our study was designed to further prove the initial finding concerning the absence of the virus in semen as the EPS is an essential part of it. The clinical features of these patients were also analyzed, with the focus on the inflammatory indicators and serum SARS-CoV-2 immunoglobins.

2. Materials and methods

2.1. Subjects

A total of 10 male inpatients with confirmed diagnosis of NCP were recruited from quarantine wards in the Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

The diagnosis of COVID-19 was confirmed by either 1) the real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) or sequencing for nasopharyngeal swabbing SARS-CoV-2 RNA [13], or 2) the positive serum immunoglobin M (IgM) or IgG antibodies of coronavirus. Patients with NCP was the patients confirmed with both COVID-19 and pneumonia diagnosed by CT scan.

Patients over 80 years or concomitant with prostatic cancer were excluded.

The maximum temperature was recorded according to the medical history given by each patient, but the pulse, respiration, blood pressure and other routine inspections were recorded at admission. The serological parameters were basically collected the second day after admission.

All subjects gave their oral and written informed consent before recruitment. This project is approved by the local ethical committee (No. Quick-PJ2020-03-35) in terms of urgent need.

2.2. The two-glass test for EPS

Although the Meares-Stamey 4-glass test is the standard method to obtain EPS, there was a study showed that the pre- and post-massage test has strong concordance with the 4-glass test [14]. Considering the time and the cost, the EPS in our study was obtained pre- and post-palpation of the prostate by digital rectal examination, which is also called “two-glass test”. Abstinence was required for at least 5 days before examination. The two operating doctors had been well trained by the urologists beforehand. The detailed operation included two steps. The initial step was the wearing of protective clothing, including the goggle and protective facial screen, one KN95 facial mask plus one surgical face mask, three surgical gloves, three shoe covers, one protective suit and one isolation gown. All procedures were supervised by the trained staffs from the Centers for Disease Control (CDC). The second step for the two-glass test was the digital rectal examination. The patients were asked to take a knee chest position after the disinfection of external urethral orifice. The urine was collected hereafter as “the first glass of urine”. Afterwards, the doctors inserted the index that lubricated with paraffin oil to the recta and palpated the prostate gently. The EPS was collected as “the second glass of EPS”.

The RT-PCR kit (DAAN Gene Co, Ltd of Sun Yat-sen University) was used for SARS-CoV-2 RNA detection in EPS. To ensure the consistent positive nasopharyngeal SARS-CoV-2, nasopharyngeal swabbing was retested within 3 days of the EPS taken day. Serum IgM and IgG were also tested.

A questionnaire on sociodemographic and sexual behaviors would be conducted if the EPS was positive.

2.3. Statistical analysis

Quantitative data were depicted as median and interquartile range (Percentile 25, Percentile 75). Statistical analyses were performed with SPSS26.0.

Table 1
The demographic and clinical data of ten male patients.

|                          | N     | Normal range |
|--------------------------|-------|--------------|
| Age (years)              | 57.50 | 50.00 (40.00, 70.00) |
| Height (cm)              | 170.00| 160.00 (150.00, 180.00) |
| Body weight (kg)         | 70.00 | 60.00 (50.00, 80.00) |
| BMI (kg/m²)              | 24.81 | 18.5 - 23.9 |
| Maximum Temperature (℃)  | 39.00 | 36 - 37 |
| Pulse (beats per minute) | 96.00 | 60 - 100 |
| Respiration (times per minute) | 20.00 | 12 - 20 |
| Systolic blood pressure (mmHg) | 127.50 | 90 - 140 |
| Diastolic blood pressure (mmHg) | 90.50 | 60 - 90 |
| Blood oxygen saturation (%) | 96.50 | > 90%

The interval between the emerge of symptoms and diagnosis (days) 11.00 (8.25, 17.00) NA

Tumor history (n) 0 NA

Heart failure history (n) 0 NA

Cerebrovascular disease history (n) 0 NA

Kidney disease history (n) 0 NA

Liver disease history (n) 2 (20.00%) NA

Diabetes (n) 5 (50.00%) NA

Hypertension (n) 2 (20.00%) NA

Chronic obstructive pulmonary disease 1 (10.00%) NA

Smoking history (n) 6 (60.00%) NA

Alcohol intaking history (n) 8 (80.00%) NA

Nursing house staying history (n) 0 NA

Unconsciousness (n) 0 NA

Pleural effusion (n) 1 (10.00%) NA

SPSS26.0.

Abbreviations: BMI: body mass index; NA: not applicable.
Immunoglobin was detected unspecifically regardless of IgM or IgG because of the shortage for specific testing kits.

*The interval between the first negative nasopharyngeal SARS-CoV-2 RNA test and the day that EPS was taken.

| Patient No. | SARS-CoV-2 RNA in urine pre-palpation | SARS-CoV-2 RNA in EPS post-palpation | Nasopharyngeal SARS-CoV-2 RNA within 3 days of prostate palpation | Serum SARS-CoV-2 IgM | Serum SARS-CoV-2 IgG | The interval (days)* |
|-------------|---------------------------------------|--------------------------------------|---------------------------------------------------------------|----------------------|----------------------|---------------------|
| 1           | Negative                              | Negative                             | Positive                                                      | Positive             | Positive             | NA                  |
| 2           | Negative                              | Negative                             | Positive                                                      | Positive             | Positive             | NA                  |
| 3           | Negative                              | Negative                             | Negative                                                      | Negative             | Positive             | 25                  |
| 4           | Negative                              | Negative                             | Negative                                                      | Negative             | Positive             | 20                  |
| 5           | Negative                              | Negative                             | Negative                                                      | Negative             | Positive             | 3                   |
| 6           | Negative                              | Negative                             | Positive                                                      | Negative             | Positive             | 18                  |
| 7           | Negative                              | Negative                             | Positive                                                      | Negative             | Positive             | 8                   |
| 8           | Negative                              | Negative                             | Positive                                                      | Positive             | Positive             | 20                  |

*The interval between the first negative nasopharyngeal SARS-CoV-2 RNA test and the day that EPS was taken.

# Immunoglobulin was detected unspecifically regardless of IgM or IgG because of the shortage for specific testing kits.

EPS: expressed prostatic secretion.

NA: not applicable.
Therefore, the interval between the latest negative SARS-CoV-2 RNA test and the day that EPS was taken was counted for the previous seven patients. The longest interval was 29 days while the latest was 3 days before the EPS test as shown in Table 3.

Serum SARS-CoV-2 IgM and IgG were also tested qualitatively during hospitalization (Table 3). Unfortunately, two patients had un-specific tests for SARS-CoV-2 immunoglobin because of the shortage for specific testing kit (shown in Table 3). There were two patients with positive nasopharyngeal SARS-CoV-2 RNA manifested positive serum IgM, while all patients had positive serum IgG (Table 3).

Unexpectedly but fortunately, none of the patients had positive COVID-19 RNA in EPS regardless of nasopharyngeal SARS-CoV-2 RNA.

4. Discussion

All patients in our study had a fever, maximum at 39.6°C, before hospitalization which supported the importance of temperature test in public area. Our data also presented increased inflammatory indicators, i.e. CRP, ESR, and IL-6 (Table 1), which has also been previously proved by other studies [15,16]. In our study, serum IgM against SARS-CoV-2 was only positive for patients in the PNS group indicating a recent infection. At present, there is no evidence for how long IgM will sustain. However, our data to some extent signified that serum IgM could be a potential and safer surrogate for nasopharyngeal swabbing SARS-CoV-2 RNA as a recent infectious indicator.

It has been raised concerns previously with respect to the male reproductive system during COVID-19 infection since the virus was verified to be related to testis damage [17]. Sexual transmission of COVID-19 has also been concerned since another pandemic pathogen, Ebola virus, was detected in semen and contagious in-between sexual partners [18]. The semen sample was still positive for Ebola virus at 565 days after discharge [19].

The EPS is secreted by prostate and is an essential component of semen, accounting for one tenth to one third volume of the ejaculation. Prostate fluid protects and nourishes the sperm cells. It would be emphasized that the EPS was negative for the SARS-CoV-2 RNA test according to our data, notwithstanding it was supposed that the prostate was one of the most susceptible organs. The SARS-CoV-2 RNA in EPS was not only negative in the PNNS group, but also negative in the PNS group. This strongly suggested the absence of SARS-CoV-2 in prostate, which possibly implied no prostate injury and the safety of the sexual behavior during COVID-19. In keeping with our data, several studies published very recently have demonstrated the negativity of SARS-CoV-2 in semen sample [11,12,19] although in vitro study had proposed the susceptibility of tests [17]. On the contrary, another recent publication reported that six COVID-19 patients had positive SARS-CoV-2 in semen samples [20]. However, the method description on the obtaining of semen samples in this publication were not fully described. Even so, this result makes the sexual transmission of SARS-CoV-2 more ambiguous. Given the fact that EPS is an important part of the semen, our results utterly supports these previous negative findings. However, it is worthy to mention that the EPS in our study independently verified the negativity of SARS-CoV-2 in the prostate which is different from semen sample in the previous findings.

Nonetheless, it would be prudent to recognize the false negative results in SARS-CoV-2 RNA test although the false negative results were more common in the nasopharyngeal swabbing RNA test in terms of non-standard swabbing operation. The potentially high false negative in the nasopharyngeal swabbing test has been raised concerns of the clinicians lately [21] since there were patients had a “turn positive” of COVID-19 test but actually had a false negative test previously [22]. Consequently, RNA tests in repetition are needed both for the nasopharyngeal swabbing and for the EPS test in the future to confirm the true negative. In addition, the relatively small sample size is a major limitation of our study in the light of the strict inclusion criteria. A larger cohort is warranted to confirm the absence of sexual transmission during COVID-19. The copy number of viruses also needs to be assessed in parallel, while Meares-Stamey 4-glass Test might also need to be operated instead of two glass tests in the future study. Another limitation of the study is the no sampling of the seminal fluid. A study with both EPS and seminal fluid is therefore called for confirming the absence of SARS-CoV-2.

Considering what we have studied is only a tip of the iceberg, more collaborative actions and scientific evidences are needed to turn this pandemic.

Funding

This research was funded by the grant from the prevention and control research emergency project of COVID-19, Medical Humanities Research Center, Anhui Medical University (“Emergency management and strategies during COVID-19” YJSK202012 to H.Z.) and the project of critical techniques on emergency rescue site during public emergencies, Anhui Medical University (201302003 to G.F. and A.X.).

Declaration of Competing Interest

The authors declare that there are no conflicts of interest.

Acknowledgements

The authors would kindly acknowledge all the doctors from doc- 2020mology department of Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, for helping out the clinical tests.

References

[1] Q. Li, X. Guan, P. Wu, et al., Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N. Engl. J. Med. (2020).
[2] C. Wang, Z. Liu, Z. Chen, et al., The establishment of reference sequence for SARS-CoV-2 and variation analysis, J. Med. Virol. (2020).
[3] J.F. Chan, S. Yuan, K.H. Kok, et al., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster, Lancet 395 (10223) (2020) 514–523.
[4] K.K. To, O.T. Tsang, C. Chik-Yan Yip, et al., Consistent detection of 2019 novel coronavirus in saliva, Clin. Infect. Dis. (2020).
[5] W.J. Guan, Z.Y. Ni, Y. Hu, et al., Clinical characteristics of 2019 novel coronavirus infection in China, N. Engl. J. Med. (2020).
[6] C. Tikellis, M.C. Thomas, Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease, Int. J. Pept. 2012 (102) p. 256294.
[7] I. Hamming, W. Timens, M.L. Bulthuis, et al., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol. 203 (2) (2004) 631–637.
[8] C. Wu, S.F. Zheng, Y. Chen, et al., Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV, in the nasal tissue, MedRxiv (2020).
[9] J.H. Kuhn, W. Li, H. Choe, et al., Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus, Cell. Mol. Life Sci. 61 (21) (2004) 2738–2743.
[10] M. Yokoyama, K. Hiwada, T. Kobuk, et al., Angiotensin-converting enzyme in human prostate, Clin. Chim. Acta 100 (3) (1980) 253–258.
[11] F. Pan, X. Xiao, J. Guo, et al., No evidence of SARS-CoV-2 in semen of males recovering from COVID-19, Fertil. Steril. (2020).
[12] C. Song, Y. Wang, W. Li, et al., Absence of 2019 novel coronavirus in semen and testes of COVID-19 patients, Biol. Reprod. (2020) ioaa050.
[13] C. Huang, Y. Wang, X. Li, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet (2020).
[14] J.C. Nickel, D. Shokes, V. Wang, et al., How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J. Urol. 176 (1) (2006) 119–124.
[15] C. Qin, L. Zhou, Z. Hu, et al., Dysregulation of immune response in patients with COVID-19 in Wuhan, China, Clin. Infect. Dis. (2020).
[16] A. Cosarizza, S. De Biasi, G. Guaraldi, et al., SARS-CoV-2, the virus that causes COVID-19: cytometry and the new challenge for global health, Cytometry A (2020).
[17] Z. Wang, X. Xu, scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in Spermatogonia, Leydig and sertoli cells, Cells 9 (4) (2020) p. 920.
[18] M.J. Soka, M.J. Choi, A. Baller, et al., Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA results and behavioural data, Lancet Glob. Health 4 (10) (2016) e736–743.
[19] D. Paoli, F. Pallotti, S. Colangelo, et al., Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab, J. Endocrinol. Invest. (2020).

[20] D. Li, M. Jin, P. Bao, et al., Clinical characteristics and results of semen tests among men with coronavirus disease 2019, JAMA Netw. Open 3 (5) (2020) p. e208292.

[21] Y. Li, L. Yao, J. Li, et al., Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19, J. Med. Virol. (2020).

[22] A.T. Xiao, Y.X. Tong, S. Zhang, False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence, J. Med. Virol. (2020).